Join to access to all OVN content. Join for Free
The Ideal Roadmap for New MSLs
Medical Science Liaisons MSL career progression personal branding digital presence MSL training

The Ideal Roadmap for New MSLs


Share This Article


Summary

In this episode, Tom Caravela is joined by Sarah Snyder, MSL Recruiter at The Carolan Group and Co-Founder of MSL Mastery who discusses an ideal road map for new Medical Science Liaisons (MSLs). They walk through the 4 stages of what a new MSL experiences in the first full year. Building the foundation in months 1 to 3, Gaining momentum in months 3-6, becoming a trusted partner in months 6-12 and driving impact/delivering results at the 1 year mark and beyond. They also discuss tools and resources for enhancing MSL career progression and development. The episode explores personal branding, social media presence, and future trends in digital as well as AI for MSLs.

Key Points

  • Establishing a well-organized home office and staying updated in your therapeutic area is crucial for new MSLs to hit the ground running.
  • Building a strong foundation through structured training and certification is essential in the initial months to set the stage for becoming a trusted partner in the field.
  • Personal branding and maintaining a professional digital presence on platforms like LinkedIn are increasingly important for career advancement and networking as an MSL.

Click for Source
Medical Science Liaisons, MSL career progression, personal branding, digital presence, MSL training

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Article
Promotability: How to Land Your Next Promotion
Partner Avatar Tom Caravela

Promotability: How to Land Your Next Promotion

Podcast
Social Media Listening Evolved
Partner Avatar MSL Talk: Tom Caravela, Conor McGladrigan, Kevin Peterson

Social Media Listening Evolved

Podcast
How to Start Presenting Like a Pro
Partner Avatar MSL Talk: Tom Caravela

How to Start Presenting Like a Pro

Article
Does biomarker use in oncology improve clinical trial failure risk? A large-scale analysis
OVN Avatar Jayson L. Parker, Sebnem S. Kuzulugil, Kirill Pereverzev, Stephen Mac, Gilberto Lopes, Zain Shah, Ashini Weerasinghe, Daniel Rubinger, Adam Falconi, Ayse Bener, Bora Caglayan, Rohan Tangri, Nicholas Mitsakakis

Does biomarker use in oncology improve clinical trial failure risk? A large-scale analysis

Article
Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval
OVN Avatar Avi Cherla, MSc; Huseyin Naci, MHS, PhD; Aaron S. Kesselheim, MD, JD, MPH; Bishal Gyawali, MD, PhD; Elias Mossialos, MD, PhD

Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval

Article
Assessment of Food and Drug Administration- and European Medicines Agency-Approved Systemic Oncology Therapies and Clinically Meaningful Improvements in Quality of Life: A Systematic Review
OVN Avatar Vanessa Arciero, BS, Seanthel Delos Santos, Liza Koshy

Assessment of Food and Drug Administration- and European Medicines Agency-Approved Systemic Oncology Therapies and Clinically Meaningful Improvements in Quality of Life: A Systematic Review

Explore OVN